Joint Formulary & PAD

Upadacitinib - Psoriatic arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Upadacitinib
Indication :
Psoriatic arthritis
Group Name :
Keywords :
JAK inhibitor, janus kinase, NICE, immunosuppressant, targeted synthetic, tsDMARD, disease modulating, rheumatology
Brand Names Include :
Rinvoq
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Other Indications

Below are listed other indications that Upadacitinib is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated  Psoriatic arthritis high cost immunomodulator treatment pathway.

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends upadacitinib as a treatment option for the treatment of Psoriatic Arthritis in line with NICE TA768.

Upadacitinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA768.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.